{"id":"W2955839328","doi":"10.1002/cncr.32190","title":"Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Bristol-Myers Squibb; Ono Pharmaceutical; National Institute for Health and Care Research; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Nivolumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Oncology; Randomized controlled trial; Clinical trial; Head and neck squamous-cell carcinoma; Target lesion; Immunotherapy; Phases of clinical research; Head and neck cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007507319,0.00144636,0.004408765,0.0005751204,0.0004617484,0.001703331,0.0007834585,0.001407239,0.002650249],"category_scores_gemma":[0.007070239,0.0005147551,0.01226392,0.0006051435,0.0006125806,0.0007562505,0.0005744934,0.00145884,0.0002837445],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009845336,"about_ca_system_score_gemma":0.001603335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007310643,"about_ca_topic_score_gemma":0.002676393,"domain_scores_codex":[0.9960749,0.00237686,0.0004392964,0.0005631792,0.0002763694,0.0002693927],"domain_scores_gemma":[0.9966239,0.001540866,0.000669082,0.000638045,0.0002142244,0.0003138761],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9427364,0.0007490774,0.006976754,0.001598846,0.03090203,0.0001092692,0.0000724623,0.000566404,0.002667147,0.00009846211,0.0007661983,0.01275683],"study_design_scores_gemma":[0.7763888,0.07261966,0.05579888,0.0004602024,0.08625818,0.0003560638,0.0001572638,0.002849037,0.001804793,0.0009047972,0.002269436,0.0001328668],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9740731,0.01936948,0.0009072377,0.0004041322,0.0004944119,0.002090764,0.001357256,0.00006791012,0.001235707],"genre_scores_gemma":[0.9941919,0.001759751,0.0005149117,0.0005060975,0.0002486733,0.001210467,0.000997054,0.00002002041,0.0005510589],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007507319,"threshold_uncertainty_score":0.03970301,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05610088972359639,"score_gpt":0.403699092824067,"score_spread":0.3475982031004706,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}